Aurore Perrot, MD, of Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France, explains the progress made in the treatment for myeloma and talks on how the rate at which drugs are being developed, advances in measurable residual disease (MRD), and improved risk-adapted strategies, may enable patients with myeloma to be cured in the future. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.